Psych CASC / OSCE · General adult psychiatry — bipolar and related disorders
Explain bipolar II, stopping the antidepressant, and starting quetiapine plus planned lamotrigine — CASC communication station
MRCPsych/FRANZCP-style communication station: plain-language bipolar II explanation, hypomania vs mania, antidepressant switch risk with STEP-BD framing, quetiapine metabolic counselling, lamotrigine slow titration and rash safety.
On this page & tools
Target exams
Station brief
Format. Communication station, approximately 7–10 minutes active time after reading. You are the psychiatry registrar in outpatient clinic. [3]
Candidate instructions. Explain bipolar II and hypomania in plain language. Explain why the antidepressant was stopped. Outline the plan for quetiapine now and lamotrigine later, including common side-effects, blood tests or monitoring, and rash safety. Check understanding and invite questions. The examiner plays the partner. [1][2][3]
Candidate scenario
Your patient has recurrent depression and clear week-long high-energy periods with little sleep need and overspending (never hospitalised, never psychotic). She was on sertraline alone and became activated. You have diagnosed bipolar II, stopped the antidepressant under supervision, started quetiapine, and plan slow lamotrigine titration after she settles. Partner asks: "Is this the severe manic illness? Why stop the only tablet that ever helped a bit? Will quetiapine make her obese? What is lamotrigine for?" [3]
Suggested structure (candidate)
- Rapport and agenda — acknowledge worry; cover diagnosis, why medicines change, monitoring, questions.
- Bipolar II in plain language — depressions plus milder high periods (hypomania); not the same as full mania needing hospital; still serious because depression and suicide risk can be high. [3]
- Why stop the antidepressant — in bipolar-type illness, antidepressants alone can push highs or mixed unstable periods; large research (STEP-BD) did not show clear long-term durable benefit from adding antidepressants to mood-stabilising treatment. [1]
- Quetiapine now — treats bipolar depression with trial evidence including bipolar II; may sedate and increase appetite/weight — lifestyle advice and metabolic blood tests/weight checks. [2][3]
- Lamotrigine later — helps prevent future depressions; must increase slowly; any concerning rash means stop and call; if stopped for over about a week, restart low. [3][4]
- Check understanding — teach-back; written information; who to contact if sleep collapses or suicidal thoughts rise.[3]
Marking domains
- Empathy, structure, jargon control
- Accurate plain-language bipolar II vs mania
- Clear rationale for stopping antidepressant monotherapy
- Balanced quetiapine benefit–risk and monitoring
- Correct lamotrigine slow titration and rash safety points
- Collaboration and checking understanding
Actor notes (partner)
Anxious that 'bipolar' means dangerous madness. Angry the antidepressant was stopped. Softens when hypomania is explained as the 'good weeks' that were not truly wellness. Asks if she will be on medicines forever and about weight gain. May interrupt with "but she was never sectioned." [3]
Common fails
- Agreeing to restart SSRI monotherapy "until she is less sad"[1]
- Equating bipolar II with lifelong institutionalised mania
- Omitting metabolic counselling for quetiapine
- Telling them to start lamotrigine at full dose tonight for quick effect
- Minimising suicide risk because "it is only bipolar II"
Debrief model line
"Bipolar II means major depressions plus milder high periods called hypomania — still a serious polarity illness, not 'mild sadness.' We stopped the antidepressant alone because it can destabilise bipolar-type mood. Quetiapine treats the depression pole with evidence in bipolar II, with weight and metabolic monitoring. Lamotrigine is added slowly later mainly to prevent the next depression, with careful rash safety." [1][2][3][4]
References
- [1]Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression N Engl J Med, 2007.PMID 17392295
- [2]Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression Am J Psychiatry, 2005.PMID 15994719
- [3]Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders Aust N Z J Psychiatry, 2021.PMID 33353391
- [4]Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder J Clin Psychiatry, 2004.PMID 15096085